SPPAM
CSTL icon

Summit Partners Public Asset Management’s Castle Biosciences CSTL Stock Holding History

Summit Partners Public Asset Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.7M Sell
824,872
-115,813
-12% -$2.58M 0.35% 82
2026
Q1 		$23.1M Sell
940,685
-118,040
-11% -$3.87M 0.62% 55
2025
Q4 		$41.2M Buy
1,058,725
+658,725
+165% +$21.2M 0.86% 42
2025
Q3 		$9.11M Buy
+400,000
New +$8.13M 0.19% 108

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

Summit Partners Public Asset Management's CSTL Position: Q2 2026 in Review

Summit Partners Public Asset Management reduced its Castle Biosciences (CSTL) stake by 12% in Q2 2026, selling an estimated $2.58M and leaving 824,872 shares worth $19.7M. The position accounts for 0.35% of the portfolio, ranked #82.

Summit Partners Public Asset Management first reported a position in CSTL in Q3 2025 and has held it in 4 quarters since. The position peaked at $41.2M in Q4 2025. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Summit Partners Public Asset Management held 824,872 shares of Castle Biosciences worth $19.7M as of Q2 2026.
  • Summit Partners Public Asset Management sold 115,813 Castle Biosciences shares in Q2 2026, an estimated $2.58M.
  • Castle Biosciences made up 0.35% of Summit Partners Public Asset Management's portfolio in Q2 2026, its #82 holding.
  • Summit Partners Public Asset Management first reported a position in Castle Biosciences in Q3 2025 and has held it in 4 quarters since.
  • Summit Partners Public Asset Management's Castle Biosciences position peaked at $41.2M in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Summit Partners Public Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.